share_log

Optimism Around ApicHope Pharmaceutical (SZSE:300723) Delivering New Earnings Growth May Be Shrinking as Stock Declines 15% This Past Week

Optimism Around ApicHope Pharmaceutical (SZSE:300723) Delivering New Earnings Growth May Be Shrinking as Stock Declines 15% This Past Week

随着股票上周下跌15%,对一品红药业(SZSE:300723)新的盈利增长前景的乐观情绪可能正在缩水。
Simply Wall St ·  08/02 20:34

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. For example, the ApicHope Pharmaceutical Co., Ltd (SZSE:300723) share price is down 35% in the last year. That's well below the market decline of 18%. Even if you look out three years, the returns are still disappointing, with the share price down33% in that time. Shareholders have had an even rougher run lately, with the share price down 30% in the last 90 days.

被动投资指数基金是确保自己的回报与整个市场大致相匹配的好方法。当你买入个股时,你可以获得更高的利润,但你也面临表现不佳的风险。例如,ApicHope制药有限公司(深圳证券交易所代码:300723)的股价在去年下跌了35%。这远低于18%的市场跌幅。即使展望三年,回报仍然令人失望,当时股价下跌了33%。股东们最近的表现更加艰难,股价在过去90天中下跌了30%。

Since ApicHope Pharmaceutical has shed CN¥1.2b from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由于ApicHope制药在过去7天中已经从其价值下跌了12元人民币,让我们看看长期下跌是否是由该企业的经济推动的。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

引用巴菲特的话说:“船只将在世界各地航行,但Flat Earth Society将蓬勃发展。市场上的价格和价值之间将继续存在巨大差异...”评估公司情绪变化的一种有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。

Unhappily, ApicHope Pharmaceutical had to report a 47% decline in EPS over the last year. The share price fall of 35% isn't as bad as the reduction in earnings per share. So the market may not be too worried about the EPS figure, at the moment -- or it may have expected earnings to drop faster.

不幸的是,ApicHope制药公司不得不报告去年每股收益下降了47%。股价下跌35%还不如每股收益的下降那么糟糕。因此,目前市场可能不太担心每股收益的数字,或者可能预计收益会更快地下降。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下图描述了 EPS 随着时间的推移是如何变化的(点击图片可以看到确切的值)。

big
SZSE:300723 Earnings Per Share Growth August 3rd 2024
SZSE: 300723 每股收益增长 2024 年 8 月 3 日

It might be well worthwhile taking a look at our free report on ApicHope Pharmaceutical's earnings, revenue and cash flow.

可能值得一看我们关于ApicHope制药收益、收入和现金流的免费报告。

A Different Perspective

不同的视角

We regret to report that ApicHope Pharmaceutical shareholders are down 34% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 18%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 5%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 3 warning signs for ApicHope Pharmaceutical that you should be aware of.

我们遗憾地报告说,ApicHope制药的股东今年下跌了34%(甚至包括股息)。不幸的是,这比整个市场18%的跌幅还要严重。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。长期投资者不会那么沮丧,因为他们本可以在五年内每年赚5%。最近的抛售可能是一个机会,因此可能值得查看基本面数据以寻找长期增长趋势的迹象。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,我们已经确定了ApicHope制药的3个警告信号,你应该注意这些信号。

We will like ApicHope Pharmaceutical better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.

如果我们看到一些大规模的内幕收购,我们会更喜欢ApicHope Pharmaceutical。在我们等待的同时,请查看这份被低估的股票(主要是小盘股)的免费清单,这些股票最近有大量的内幕买盘。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对这篇文章有反馈吗?担心内容吗?直接联系我们。或者,发送电子邮件至 editorial-team@simplywallst.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发